Laboratory Markers Indicating Gastrointestinal Involvement of Henoch-Schönlein Purpura in Children
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To determine clinically useful biochemical markers reflecting disease activity and/or gastrointestinal (GI) tract involvement in Henoch-Schönlein purpura (HSP). Methods: A total of 185 children with HSP and 130 controls were included. Laboratory data indicating inflammation, standard coagulation, and activated coagulation were analyzed for the HSP patients, including measurements of the hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelet count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, prothrombin time, activated partial thromboplastin time, and fibrinogen, D-dimer, and fibrin degradation product (FDP) levels. The clinical scores of the skin, joints, abdomen, and kidneys were assessed during the acute and convalescence phases of HSP.Results: The WBC count, ANC, ESR, and CRP, fibrinogen, D-dimer, and FDP levels were significantly higher in the acute phase compared with the convalescent phase of HSP (p<0.05). The total clinical scores were more strongly correlated with the D-dimer (r=0.371, p<0.001) and FDP (r=0.369, p<0.001) levels than with inflammatory markers, such as the WBC count (r=0.241, p=0.001), ANC (r=0.261, p<0.001), and CRP (r=0.260, p<0.001) levels. The pa-tients with GI symptoms had significantly higher ANC (median [interquartile range], 7,138.0 [4,446.4-9,470.0] vs. 5,534.1 [3,263.0-8,153.5], p<0.05) and CRP (0.49 [0.15-1.38] vs. 0.23 [0.01-0.67], p<0.05), D-dimer (2.63 [1.20-4.09] vs. 1.75 [0.62-3.39]), and FDP (7.10 [0.01-13.65] vs. 0.10 [0.01-7.90], p<0.05) levels than those without GI symptoms.Conclusion: D-dimer and FDPs are more strongly associated with disease activity and more consistently reflect GI involvement than inflammatory markers during the acute phase of HSP.
Abstract
Purpose: To determine clinically useful biochemical markers reflecting disease activity and/or gastrointestinal (GI) tract involvement in Henoch-Schönlein purpura (HSP). Methods: A total of 185 children with HSP and 130 controls were included. Laboratory data indicating inflammation, standard coagulation, and activated coagulation were analyzed for the HSP patients, including measurements of the hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelet count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, prothrombin time, activated partial thromboplastin time, and fibrinogen, D-dimer, and fibrin degradation product (FDP) levels. The clinical scores of the skin, joints, abdomen, and kidneys were assessed during the acute and convalescence phases of HSP.Results: The WBC count, ANC, ESR, and CRP, fibrinogen, D-dimer, and FDP levels were significantly higher in the acute phase compared with the convalescent phase of HSP (p<0.05). The total clinical scores were more strongly correlated with the D-dimer (r=0.371, p<0.001) and FDP (r=0.369, p<0.001) levels than with inflammatory markers, such as the WBC count (r=0.241, p=0.001), ANC (r=0.261, p<0.001), and CRP (r=0.260, p<0.001) levels. The pa-tients with GI symptoms had significantly higher ANC (median [interquartile range], 7,138.0 [4,446.4-9,470.0] vs. 5,534.1 [3,263.0-8,153.5], p<0.05) and CRP (0.49 [0.15-1.38] vs. 0.23 [0.01-0.67], p<0.05), D-dimer (2.63 [1.20-4.09] vs. 1.75 [0.62-3.39]), and FDP (7.10 [0.01-13.65] vs. 0.10 [0.01-7.90], p<0.05) levels than those without GI symptoms.Conclusion: D-dimer and FDPs are more strongly associated with disease activity and more consistently reflect GI involvement than inflammatory markers during the acute phase of HSP.
참고문헌 (25)
- Mills JA, "The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura", Arthritis Rheum, 33, pp.1114~1121 (1990)
- Ozen S, "EULAR", PReS endorsed consensus criteria for the classification of childhood vasculitides, 2006, pp.65, 936~941
- 김성우, "Henoch-Schonlein Purpura 환아에서 복통의 유무에 따른임상양상과 예후의 차이", Pediatric Gastroenterology, Hepatology & Nutrition, 14(4), pp.359~367 (2011), 대한소아소화기영양학회
- Trapani S, "Henoch Schonlein purpura in childhood:epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature", Semin Arthritis Rheum, 35, pp.143~153 (2005)
- Calviño MC, "Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study", Medicine (Baltimore), 80, pp.279~290 (2001)
- Hung SP, "Clinical manifestations and outcomes of Henoch-Schönlein purpura: comparison between adults and children", Pediatr Neonatol, 50, pp.162~168 (2009)
- Martinez-Frontanilla LA, "Surgical complications in Henoch-Schönlein Purpura", J Pediatr Surg, 19, pp.434~436 (1984)
- Faille-Kuyber EH, "IgA-deposits in cutaneous blood-vessel walls and mesangium in Henoch-Schönlein syndrome", Lancet, 1, pp.892~893 (1973)
- Besbas N, "The role of cytokines in Henoch Schonlein purpura", Scand J Rheumatol, 26, pp.456~460 (1997)
- Claudy A., "Coagulation and fibrinolysis in cutaneous vasculitis", Clin Dermatol, 17, pp.615~618 (1999)
- Ateş E, "von Willebrand factor antigen compared with other factors in vasculitic syndromes", Arch Dis Child, 70, pp.40~43 (1994)
- Hergesell O, "Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis", Thromb Haemost, 75, pp.892~898 (1996)
- Rose PE, "Factor VIII von Willebrand protein in haemolytic uraemic syndrome and systemic vasculitides", Lancet, 335, pp.500~502 (1990)
- De Mattia D, "von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura", Pediatr Nephrol, 9, pp.603~605 (1995)
- Yilmaz D, "The elevated markers of hypercoagulability in children with Henoch-Schönlein purpura", Pediatr Hematol Oncol, 22, pp.41~48 (2005)
- Saulsbury FT, "Henoch-Schönlein purpura", Curr Opin Rheumatol, 22, pp.598~602 (2010)
- Yang YH, "The immunobiology of Henoch-Schönlein purpura", Autoimmun Rev, 7, pp.179~184 (2008)
- Yang YH, "The diagnosis and classification of Henoch-Schönlein purpura: an updated review", Autoimmun Rev, 13, pp.355~358 (2014)
- Levi M, "Two-way interactions between inflammation and coagulation", Trends Cardiovasc Med, 15, pp.254~259 (2005)
- Szaba FM, "Roles for thrombin and fibrin(ogen) in cytokine", chemokine production and macrophage adhesion in vivo, 2002, pp.99, 1053~1059
- Del Vecchio GC, "Cytokine pattern and endothelium damage markers in Henoch-Schönlein purpura", Immunopharmacol Immunotoxicol, 30, pp.623~629 (2008)
- Dalens B, "Diagnostic and prognostic value of fibrin stabilising factor in Schönlein-Henoch syndrome", Arch Dis Child, 58, pp.12~14 (1983)
- Kamitsuji H, "Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schönlein purpura. Efficacy of factor XIII substitution", Eur J Pediatr, 146, pp.519~523 (1987)
- Brendel-Müller K, "Laboratory signs of activated coagulation are common in Henoch-Schönlein purpura", Pediatr Nephrol, 16, pp.1084~1088 (2001)
- 강윤, "Differences in Clinical Manifestations and Outcomes between Adult and Child Patients with Henoch-Schönlein Purpura", Journal of Korean Medical Science, 29(2), pp.198~203 (2014), 대한의학회